## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%); PEG 1.05 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($320.07)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Does FDA’s UPLIZNA gMG Expansion Reshape the Bull Case for Amgen’s Diversification Story (AMGN)?**
- Source: Simply Wall Street | 20251226T023840 | Somewhat-Bullish | Relevance: 100%
- The FDA's approval of Amgen's UPLIZNA for generalized myasthenia gravis, targeting AChR- and MuSK-antibody positive adults, significantly boosts the company's autoimmune portfolio. This expansion supports Amgen's strategy to diversify revenue beyond its established bone-health and oncology franchises, reinforcing its investment narrative amidst ongoing biosimilar and pricing pressures. While the approval strengthens Amgen's pipeline breadth, its long-term impact will depend on how effectively it offsets challenges from maturing legacy products and regulatory scrutiny on drug prices.

**2. Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know**
- Source: The Globe and Mail | 20251224T170741 | Bullish | Relevance: 100%
- Amgen has reached a significant agreement with the Trump administration to lower drug prices in the U.S., aligning prices with other developed countries and offering substantial discounts to American consumers. This deal, which also includes an exemption from import tariffs on pharmaceutical ingredients for participating companies expanding domestic manufacturing, addresses key concerns around drug pricing and tariffs. Several other large pharmaceutical companies have made similar agreements, signaling a more cooperative environment between the government and the pharma sector.

**3. Amgen Strikes Drug Pricing Deal With Trump: What Investors Should Know**
- Source: TradingView — Track All Markets | 20251224T150750 | Bullish | Relevance: 100%
- Amgen has signed a deal with the Trump administration to lower drug prices in the U.S., addressing concerns about pricing and tariffs. This agreement involves aligning drug prices with those in other developed countries and offering discounts through direct-to-consumer channels and TrumpRx.gov. Amgen is expanding access to its discounted programs for key drugs like Repatha, Aimovig, and Amjevita, and other major drugmakers have pursued similar agreements for tariff exemptions contingent on expanding domestic manufacturing.

**4. Amgen Inc. $AMGN Shares Sold by Meyer Handelman Co.**
- Source: MarketBeat | 20251227T124042 | Somewhat-Bullish | Relevance: 100%
- Meyer Handelman Co. recently reduced its stake in Amgen Inc. (NASDAQ:AMGN) by 3.0%, selling 3,881 shares but still holding 124,913 shares valued at around $35.25 million, making Amgen its 28th largest holding. Amgen has demonstrated strong financial performance, beating quarterly earnings expectations and raising its quarterly dividend. The company also maintains a "Moderate Buy" consensus rating from analysts with a target price of $332.85.

**5. Carnegie Investment Counsel Has $30.27 Million Stake in Amgen Inc. $AMGN**
- Source: MarketBeat | 20251227T102553 | Bullish | Relevance: 100%
- Carnegie Investment Counsel significantly increased its stake in Amgen Inc. (NASDAQ:AMGN) during Q3, now holding 107,260 shares valued at $30.27 million. This move comes as Amgen reported strong Q3 earnings, beating estimates with $5.64 EPS, and analysts maintain a "Moderate Buy" consensus with an average price target of $332.85. The company also raised its quarterly dividend to $2.52 per share, despite recent insider selling activity.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-12 | Morgan Stanley | $304 | $329 | -8% |
| 2025-12-10 | Wells Fargo | $325 | $300 | +8% |
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-12 | Morgan Stanley | main | Equal-Weight |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |
| 2025-12-03 | BMO Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.05 suggests fair value with growth premium. Forward P/E 15.2x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +10%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $179.3B |
| Beta | 0.45 |
| 52W Range | $257.05 - $346.38 |
| Short Interest | 2.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.05 |
| Forward P/E | 15.2 |
| Current P/E | 15.7 |
| YoY Growth | 3.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.6% to 0.1% (-1.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.1% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.13% (CS: 76) | Neutral |
| RSI_14 | 56.6 | Neutral |
| MACD Histogram | 0.22 | Bullish |
| vs SMA20 | 1.012x | Above |
| vs SMA50 | 1.036x | Above |
| vs SMA200 | 1.119x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $332.93
- **Stop Loss:** $320.07 (3.9% risk)
- **Target:** $345.79 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 102
- **Position Value:** $33,958.86
- **Portfolio %:** 33.96%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*